Medical Research
Glioblastoma Remission Rates Remain Challenging Despite Treatment Advances
Only 25% of glioblastoma patients experience remission lasting at least two years, highlighting the urgent need for improved treatments for this aggressive brain cancer.
Circadian Rhythm Disruptions Linked to Increased Cardiometabolic Disease Risk, American Heart Association Warns
The American Heart Association's new scientific statement reveals that disruptions to the body's internal clock significantly increase risks for obesity, Type 2 diabetes, high blood pressure and cardiovascular disease, highlighting the importance of circadian alignment for preventive health strategies.
Dr. Hos Loftus Earns 2025 Castle Connolly Top Doctor Recognition for Integrated Neurology and Psychology Care
Dr. Hos Loftus has been recognized as a 2025 Castle Connolly Top Doctor for his innovative integrated approach to neurological and psychological care at Carolinas Institute for Neurology and Psychology, highlighting the growing importance of holistic treatment models in modern healthcare.
Nanomedicine Breakthroughs Transform Cancer Drug Delivery and Bioavailability
Recent advancements in nanomedicine technology are revolutionizing oncology treatment by improving drug delivery systems, enhancing bioavailability, and potentially transforming underperforming cancer drugs into effective therapies through platforms like Oncotelic Therapeutics' Deciparticle.
Study Reveals Chemotherapy May Damage Brain's Waste Drainage System, Explaining 'Chemo Brain' Symptoms
New research identifies chemotherapy-induced damage to the brain's waste drainage network as a potential cause of cognitive difficulties affecting up to 75% of cancer patients during and after treatment.
Soligenix's HyBryte Shows Promise as Potential First-Line Treatment for Cutaneous T-Cell Lymphoma
Soligenix Inc. is advancing HyBryte as a potential first-line therapy for early-stage cutaneous T-cell lymphoma following promising results from clinical trials that could reshape treatment standards in the rare disease space.
Chinese Surgical Innovations Transform Treatment for Previously Inoperable Liver Conditions
Advanced extracorporeal liver surgery techniques developed in China are providing new hope for patients with complex liver tumors and parasitic diseases previously considered surgically untreatable, eliminating the need for donor organs and lifelong immunosuppression.
New Melanoma Test Shows Three-Fold Improvement in Predicting Lymph Node Metastasis Risk
The Merlin CP-GEP test accurately stratifies melanoma patients by sentinel node metastasis risk, potentially reducing unnecessary surgical procedures through improved personalized care.
Updated Pediatric and Neonatal CPR Guidelines Emphasize Unique Needs of Children
The American Heart Association and American Academy of Pediatrics have released updated CPR and emergency cardiovascular care guidelines that provide specific recommendations for infants and children, addressing the approximately 27,000 pediatric cardiac arrests occurring annually in the United States.
Oncotelic Therapeutics Announces Three Abstracts on Deciparticle Everolimus Accepted for 2025 San Antonio Breast Cancer Symposium
Oncotelic Therapeutics will present three abstracts on its investigational intravenous Deciparticle everolimus at the 2025 San Antonio Breast Cancer Symposium, highlighting potential improvements over existing mTOR inhibitors for metastatic breast cancer treatment.
Inaugural Jack Sarver Prizes Awarded to St. Louis and Dallas Researchers for Cardiovascular Disease Prevention Studies
Two scientists from Washington University and UT Southwestern received the first Jack Sarver Prizes for research addressing maternal mortality in Nigeria through aspirin prophylaxis and identifying genetic mechanisms linking liver disease to atherosclerosis.
Branded Legacy Advances FDA Pathway for Low-Cost Intranasal Naloxone Alternative
Branded Legacy's subsidiary BioLegacy Evaluative Group is preparing FDA submission materials for a proprietary intranasal naloxone spray that aims to replicate Narcan's performance while reducing costs and improving global accessibility to opioid overdose reversal medication.
Updated CPR Guidelines Introduce Major Changes to Choking Response and Opioid Overdose Treatment
The American Heart Association's 2025 CPR guidelines introduce significant updates including new choking protocols for all ages, expanded opioid overdose response with naloxone guidance, and a unified chain of survival system that could improve survival rates for the 350,000 annual out-of-hospital cardiac arrests in the U.S.
Nanoparticle Breakthrough Offers New Hope for Alcohol-Related Liver Disease Treatment
Researchers have developed innovative nanoparticles that could combat scarring and inflammation in alcohol-related liver disease, potentially creating a treatment template applicable to other organs.
Survey Reveals Widespread Unawareness of CKM Syndrome Affecting Nearly 90% of U.S. Adults
A new American Heart Association survey shows 90% of U.S. adults are unaware of cardiovascular-kidney-metabolic syndrome, a condition affecting nearly 90% of the population that significantly increases heart attack and stroke risk.
Digital Tumor Twins Promise Personalized Brain Cancer Treatment Breakthrough
Cedars-Sinai is developing virtual brain tumor replicas that could revolutionize cancer treatment by predicting tumor growth and therapy responses, potentially improving outcomes for patients with difficult-to-treat cancers like glioblastoma.
University of Calgary Seeks 10,000 Toenail Samples for Radon Exposure and Lung Cancer Study
Canadian researchers are collecting toenail samples to develop better methods for measuring radon exposure and its connection to lung cancer risk, potentially enabling earlier diagnosis and treatment.
GeoVax Reports Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients
GeoVax Labs announced promising Phase 2 clinical trial results showing its multi-antigen COVID-19 vaccine candidate demonstrates strong safety and robust T-cell responses in immunocompromised patients, potentially addressing a critical gap in protection for vulnerable populations.
Soligenix Strengthens Medical Advisory Board to Advance HyBryte CTCL Treatment Through Phase 3 Development
Soligenix has updated its U.S. Medical Advisory Board with leading dermatologic and oncologic experts to guide the Phase 3 development and potential commercialization of HyBryte, a novel photodynamic therapy for cutaneous T-cell lymphoma that addresses significant unmet medical needs.
Women Face Significant Barriers in Cardiac Rehabilitation Access Despite Proven Health Benefits
A new scientific statement reveals women face substantial obstacles in accessing cardiac rehabilitation programs despite experiencing greater mortality reductions than men, highlighting urgent need for systemic changes to improve cardiovascular outcomes for female patients.
Harvard AI System Revolutionizes Brain Tumor Diagnosis During Surgery
Harvard Medical School researchers have developed an AI tool called PICTURE that achieves 99.8% accuracy in distinguishing between glioblastoma and primary central nervous system lymphoma during surgery, potentially transforming treatment outcomes for brain cancer patients.
Cancer Treatment Support Needs Drive Biotech Innovation
The emotional and physical challenges faced by cancer patients during treatment are motivating biotech companies like Soligenix to develop new therapeutic approaches while highlighting the importance of patient-focused support strategies.
Glioblastoma Found to Erode Skull Tissue, Challenging Long-Held Treatment Assumptions
A recent study reveals that glioblastoma, the deadliest form of brain cancer, erodes patients' skulls, challenging the long-held assumption that the disease is localized and potentially explaining why current therapies have shown dismal success rates.
Soligenix Expands European Medical Advisory Board to Advance CTCL Treatment Development
Soligenix is strengthening its European medical advisory board and advancing Phase 3 clinical trials for HyBryte, a potential new treatment for cutaneous T-cell lymphoma that addresses significant unmet medical needs in European patients.
GeoVax to Present COVID-19 Vaccine Data for Immunocompromised Patients at European Vaccine Congress
GeoVax Labs will present interim safety data and special-population insights for its GEO-CM04S1 COVID-19 vaccine at the World Vaccine Congress Europe 2025, highlighting progress in addressing vaccine needs for immunocompromised patients where current options remain insufficient.
New Research Identifies Key Mechanism Behind Cancer Immunotherapy Failures
Ohio State University researchers have discovered a previously unknown stress pathway that explains why immunotherapy fails in most cancer patients, potentially paving the way for more effective treatments.
Oncotelic Therapeutics Announces Phase 1 Trial Enrollment for Novel Intravenous Everolimus Formulation in Australia
Oncotelic Therapeutics has opened enrollment for the first clinical trial of Sapu-003, an intravenous Deciparticle formulation of everolimus that represents a significant advancement in mTOR-targeted cancer therapy delivery for patients with advanced breast cancer and other malignancies.
UT Southwestern Cardiologist Amit Khera Receives Prestigious 2025 Chairman's Award from American Heart Association
Dr. Amit Khera's recognition highlights his transformative contributions to preventive cardiology, including developing NASA's astronaut heart risk calculator and advancing cardiovascular disease prevention through innovative research and leadership.
Soligenix's HyBryte Therapy Shows Positive Safety Profile in Phase 3 CTCL Trial
Soligenix's HyBryte therapy demonstrated a positive safety profile in its ongoing Phase 3 FLASH2 study for cutaneous T-cell lymphoma, maintaining progress toward potential regulatory approval and commercialization as a first-line treatment option.
Lund University Researchers Identify Mechanism Allowing Leukemia Cells to Evade Immune System
Researchers at Lund University have discovered why acute myeloid leukemia cells resist immunotherapy, potentially paving the way for more effective treatments for this aggressive blood cancer.